Is gemcitabine cost effective in cancer treatment?

References

• Crino L, Scagliotti GV, Ricci S et al. Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: a randomized Phase III study of the Italian Lung Cancer Project. J. Clin. Oncol.17(11), 3522–3530 (1999).
   PubMed Web of Science ®Google Scholar
• Cardenal F, Lopez-Cabrerizo MP, Anton A et al. Randomized Phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer. J. Clin. Oncol.17(1), 12–18 (1999).
   PubMed Web of Science ®Google Scholar
• Burris HA 3rd, Moore MJ, Andersen J et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol.15(6), 2403–2413 (1997).
   PubMed Web of Science ®Google Scholar
• Pfisterer J, Plante M, Vergote I et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J. Clin. Oncol.24(29), 4699–4707 (2006).
   PubMed Web of Science ®Google Scholar
• Albain KS, Nag S, Calderillo-Ruiz G et al. Global phase III study of gemcitabine plus paclitaxel vs. paclitaxel as frontline therapy for metastatic breast cancer: first report of overall survival. Proc. Am. Soc. Clin. Oncol.23(5), A510 (2004).
   Web of Science ®Google Scholar
• Von der Maase H, Hansen SW et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, Phase III study. J. Clin. Oncol.18(17), 3068–3077 (2000).
   PubMed Web of Science ®Google Scholar
• Gatzemeier U, Shepherd FA, Le Chevalier T et al. Activity of gemcitabine in patients with non-small cell lung cancer: a multicentre, extended Phase II study. Eur. J. Cancer32A(2), 243–248 (1996).
   PubMed Web of Science ®Google Scholar
• Abratt RP, Bezwoda WR, Falkson G, Goedhals L, Hacking D, Rugg TA. Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a Phase II study. J. Clin. Oncol.12(8), 1535–1540 (1994).
   PubMed Web of Science ®Google Scholar
• Shepherd FA, Abratt RP, Anderson H, Gatzemeier U, Anglin G, Iglesias J. Gemcitabine in the treatment of elderly patients with advanced non-small cell lung cancer. Semin. Oncol.24(2 Suppl.7), S750–S755 (1997).
   Google Scholar
• Anderson H, Hopwood P, Stephens RJ et al. Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer–a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Non-small cell lung cancer. Br. J. Cancer83(4), 447–453 (2000).
   PubMed Web of Science ®Google Scholar
• Lees M, Aristides M, Maniadakis N, McKendrick J, Botwood N, Stephenson D. Economic evaluation of gemcitabine alone and in combination with cisplatin in the treatment of nonsmall cell lung cancer. Pharmacoeconomics20(5), 325–337 (2002).
   PubMed Web of Science ®Google Scholar
• Clegg A, Scott DA, Hewitson P, Sidhu M, Waugh N. Clinical and cost effectiveness of paclitaxel, docetaxel, gemcitabine, and vinorelbine in non-small cell lung cancer: a systematic review. Thorax57(1), 20–28 (2002).
   PubMed Web of Science ®Google Scholar
• Berthelot JM, Will BP, Evans WK, Coyle D, Earle CC, Bordeleau L. Decision framework for chemotherapeutic interventions for metastatic non-small-cell lung cancer. J. Natl Cancer. Inst.92(16), 1321–1329 (2000).
   PubMed Web of Science ®Google Scholar
• Manegold C, Bergman B, Chemaissani A et al. Single-agent gemcitabine versus cisplatin-etoposide: early results of a randomised Phase II study in locally advanced or metastatic non-small-cell lung cancer. Ann. Oncol.8(6), 525–529 (1997).
   PubMed Web of Science ®Google Scholar
• Perng RP, Chen YM, Ming-Liu J et al. Gemcitabine versus the combination of cisplatin and etoposide in patients with inoperable non-small-cell lung cancer in a Phase II randomized study. J. Clin. Oncol.15(5), 2097–2102 (1997).
   PubMed Web of Science ®Google Scholar
• Vansteenkiste JF, Vandebroek JE, Nackaerts KL et al. Clinical-benefit response in advanced non-small-cell lung cancer: a multicentre prospective randomised Phase III study of single agent gemcitabine versus cisplatin–vindesine. Ann. Oncol.12(9), 1221–1230 (2001).
   PubMed Web of Science ®Google Scholar
• Dooms CA, Lievens YN, Vansteenkiste JF. Cost–utility analysis of chemotherapy in symptomatic advanced nonsmall cell lung cancer. Eur. Respir. J.27(5), 895–901 (2006).
   PubMed Web of Science ®Google Scholar
• Koch P, Johnson N, van Schaik J et al. Gemcitabine: clinical and economic impact in inoperable non-small cell lung cancer. Anticancer Drugs6(Suppl. 6), 49–54 (1995).
   Google Scholar
• Copley-Merriman C, Corral J, King K et al. Economic value of gemcitabine compared to cisplatin and etoposide in non-small cell lung cancer. Lung Cancer14(1), 45–61 (1996).
   Google Scholar
• Copley-Merriman C, Martin C, Johnson N, Sacristan JA, Drings PA, Bosanquet N. Economic value of gemcitabine in non-small cell lung cancer. Semin. Oncol.23(5 Suppl. 10), 90–98 (1996).
   Google Scholar
• Tennvall GR, Fernberg JO. Economic evaluation of gemcitabine single agent therapy compared with standard treatment in Stage IIIB and IV non-small cell lung cancer. Med. Oncol.15(2), 129–136 (1998).
   Google Scholar
• Sandler AB, Nemunaitis J, Denham C et al. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J. Clin. Oncol.18(1), 122–130 (2000).
   PubMed Web of Science ®Google Scholar
• Schiller JH, Harrington D, Belani CP et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N. Engl. J. Med.346(2), 92–98 (2002).
   PubMed Web of Science ®Google Scholar
• Scagliotti GV, De Marinis F, Rinaldi M et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J. Clin. Oncol.20(21), 4285–4291 (2002).
   PubMed Web of Science ®Google Scholar
• Comella P, Frasci G, Panza N et al. Randomized trial comparing cisplatin, gemcitabine, and vinorelbine with either cisplatin and gemcitabine or cisplatin and vinorelbine in advanced non-small-cell lung cancer: interim analysis of a Phase III trial of the Southern Italy Cooperative Oncology Group. J. Clin. Oncol.18(7), 1451–1457 (2000).
   PubMedGoogle Scholar
• Schiller J, Tilden D, Aristides M et al. Retrospective cost analysis of gemcitabine in combination with cisplatin in non-small cell lung cancer compared to other combination therapies in Europe. Lung Cancer43(1), 101–112 (2004).
   PubMed Web of Science ®Google Scholar
• Novello S, Kielhorn A, Stynes G et al. Italian Lung Cancer Project Investigators. Cost-minimisation analysis comparing gemcitabine/cisplatin, paclitaxel/carboplatin and vinorelbine/cisplatin in the treatment of advanced non-small cell lung cancer in Italy. Lung Cancer48(3), 379–387 (2005).
   PubMed Web of Science ®Google Scholar
• Pimentel FL, Bhalla S, Laranjeira L, Guerreiro M. Cost-minimization analysis for Portugal of five doublet chemotherapy regimens from two Phase III trials in the treatment of advanced non-small cell lung cancer. Lung Cancer52(3), 365–371 (2006).
   PubMed Web of Science ®Google Scholar
• Martoni A, Marino A, Sperandi F et al. Multicentre randomised Phase III study comparing the same dose and schedule of cisplatin plus the same schedule of vinorelbine or gemcitabine in advanced non-small cell lung cancer. Eur. J. Cancer41(1), 81–92 (2005).
   PubMed Web of Science ®Google Scholar
• Gebbia V, Galetta D, Caruso et al. Phase III trial comparing cisplatin (CDDP) plus weekly vinorelbine (VNR) and CDDP plus 1+8 schedule in advanced non small cell lung cancer (NSCLC). Lung Cancer41(Suppl. 2), 63 (2003) (Abstract O216).
   Google Scholar
• Gridelli C, Gallo C, Shepherd FA et al. Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: a Phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol.21(16), 3025–3034 (2003).
   PubMed Web of Science ®Google Scholar
• Cappuzzo F, Novello S, De Marinis F et al. A randomized Phase II trial evaluating standard (50 mg/min) versus low (10 mg/min) infusion duration of gemcitabine as first-line treatment in advanced non-small-cell lung cancer patients who are not eligible for platinum-based chemotherapy. Lung Cancer52(3), 319–325 (2006).
   PubMed Web of Science ®Google Scholar
• Georgoulias V, Papadakis E, Alexopoulos A et al. Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial. Lancet357(9267), 1478–1484 (2001).
   PubMed Web of Science ®Google Scholar
• Chen YM, Perng RP, Lee YC et al. Paclitaxel plus carboplatin, compared with paclitaxel plus gemcitabine, shows similar efficacy while more cost-effective: a randomized Phase II study of combination chemotherapy against inoperable non-small-cell lung cancer previously untreated. Ann. Oncol.13(1), 108–115 (2002).
   PubMedGoogle Scholar
• Kosmidis P, Mylonakis N, Nicolaides C et al. Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: a Phase III randomized trial. J. Clin. Oncol.20(17), 3578–3585 (2002).
   PubMed Web of Science ®Google Scholar
• Smit EF, van Meerbeeck JP, Lianes P et al. Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a Phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group–EORTC 08975. J. Clin. Oncol.21(21), 3909–3917 (2003).
   PubMed Web of Science ®Google Scholar
• Neymark N, Lianes P, Smit EF, van Meerbeeck JP. Economic evaluation of three two-drug chemotherapy regimens in advanced non-small-cell lung cancer. Pharmacoeconomics23(11), 1155–1166 (2005).
   PubMed Web of Science ®Google Scholar
• Glimelius B, Hoffman K, Sjoden PO et al. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann. Oncol.7(6), 593–600 (1996).
   PubMed Web of Science ®Google Scholar
• Palmer KR, Kerr M, Knowles G, Cull A, Carter DC, Leonard RC. Chemotherapy prolongs survival in inoperable pancreatic carcinoma. Br. J. Surg.81(6), 882–885 (1994).
   PubMed Web of Science ®Google Scholar
• Heinemann V, Hinke A, Boeck S, Louvet C. Benefit from gemcitabine-based combination treatment in advanced pancreatic cancer: A meta-analysis of randomized trials. ASCO Gastrointestinal Cancers Symposium. Orlando, FL, USA, 19–21 January 2007 (Abstract 129).
   Google Scholar
• Ragnarson-Tennvall G, Wilking N. Treatment of locally advanced pancreatic carcinoma in Sweden. A health economic comparison of palliative treatment with best supportive care versus palliative treatment with gemcitabine in combination with best supportive care. Pharmacoeconomics15(4), 377–384 (1999).
   Google Scholar
• Aristides M, Lees M, Botwood N, McKendrick J, Stephenson DA, Maniadakis N. Economic evaluation of gemcitabine in the treatment of pancreatic cancer in the UK. Eur. J. Health Econ.4(3), 216–221 (2003).
   PubMedGoogle Scholar
• Trippoli S, Messori A. Cost–effectiveness of gemcitabine as first-line therapy for patients with advanced pancreatic cancer. Value Health2, 22 (1999).
   Google Scholar
• Ward S, Morris E, Bansback N et al. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of gemcitabine for the treatment of pancreatic cancer. Health Technol. Assess.5(24), 1–70 (2001).
   PubMedGoogle Scholar
• Ishii H, Furuse J, Kinoshita T et al. Treatment cost of pancreatic cancer in Japan: analysis of the difference after the introduction of gemcitabine. Jpn. J. Clin. Oncol.35(9), 526–530 (2005).
   Google Scholar
• Moore MJ, Goldstein D, Hamm J et al. Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer. A Phase III trial of the National Cancer Institute of Canada Clinical Trials Group [NCIC-CTG]. Proc. Am. Soc. Clin. Oncol.23(Suppl. 1) (2005) (Abstract 1).
   Google Scholar
• Grubbs SS, Grusenmeyer PA, Petrelli NJ, Gralla RJ. Is it cost-effective to add erlotinib to gemcitabine in advanced pancreatic cancer? Proc. Am. Soc. Clin. Oncol.24, S18, (2006) (Abstract 6048).
   Google Scholar
• Krzyzanowska MK, Earle CC, Kuntz KM, Weeks JC. Using economic analysis to evaluate the potential of multimodality therapy for elderly patients with locally advanced pancreatic cancer. Int. J. Radiat. Oncol. Biol. Phys.67(1), 211–218 (2007).
   PubMed Web of Science ®Google Scholar
• Lund B, Hansen OP, Neijt JP, Theilade K, Hansen M. Phase II study of gemcitabine in previously platinum-treated ovarian cancer patients. Anticancer Drugs6(Suppl. 6), 61–62 (1995).
   PubMedGoogle Scholar
• Friedlander M, Millward MJ, Bell D et al. A Phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer. Ann. Oncol.9(12), 1343–1345 (1998).
   PubMed Web of Science ®Google Scholar
• Prasad M, Ben-Porat L, Hoppe B et al. Costs of treatment and outcomes associated with second-line therapy and greater for relapsed ovarian cancer. Gynecol. Oncol.93(1), 223–228 (2004).
   Google Scholar
• Carmichael J, Possinger K, Phillip P et al. Advanced breast cancer: a Phase II trial with gemcitabine. J. Clin. Oncol.13(11), 2731–2736 (1995).
   PubMed Web of Science ®Google Scholar
• Possinger K, Kaufmann M, Coleman R et al. Phase II study of gemcitabine as first-line chemotherapy in patients with advanced or metastatic breast cancer. Anticancer Drugs10(2), 155–162 (1999).
   PubMed Web of Science ®Google Scholar
• Valerio MR, Cicero G, Armata MG et al. Gemcitabine(G) in pretreated breast cancer (BC). Proc. Am. Soc. Clin. Oncol.20(51B) (2001) (Abstract 1953).
   Google Scholar
• Blackstein M, Vogel CL, Ambinder R, Cowan J, Iglesias J, Melemed A. Gemcitabine as first-line therapy in patients with metastatic breast cancer: a Phase II trial. Oncology62(1), 2–8 (2002).
   PubMed Web of Science ®Google Scholar
• Spielmann M, Llombart-Cussac A, Kalla S et al. Single-agent gemcitabine is active in previously treated metastatic breast cancer. Oncology60(4), 303–307 (2001).
   PubMed Web of Science ®Google Scholar
• Brodowicz T, Kostler WJ, Moslinger R et al. Single-agent gemcitabine as second- and third-line treatment in metastatic breast cancer. Breast9(6), 338–342 (2000).
   PubMed Web of Science ®Google Scholar
• Schmid P, Akrivakis K, Flath B et al. Phase II trial of gemcitabine as prolonged infusion in metastatic breast cancer. Anticancer Drugs.10(7), 625–631 (1999).
   PubMed Web of Science ®Google Scholar
• Gerson R, Serrano OA, Villalobos A, Ortiz C, Sánchez-Forgach E. Gemcitabine response in advanced breast cancer in relation to immunohistochemical factors. Proc. Am. Soc. Clin. Oncol.19 (2000) (Abstract 572).
   Google Scholar
• Modi S, Currie VE, Seidman AD et al. A Phase II trial of gemcitabine in patients with metastatic breast cancer previously treated with an anthracycline and taxane. Clin. Breast Cancer6(1), 55–60 (2005).
   PubMed Web of Science ®Google Scholar
• Rha SY, Moon YH, Jeung HC et al. Gemcitabine monotherapy as salvage chemotherapy in heavily pretreated metastatic breast cancer. Breast Cancer Res. Treat.90(3), 215–221 (2005).
   PubMed Web of Science ®Google Scholar
• Chan S, Romieu G, Huober J et al. Gemcitabine plus docetaxel versus capecitabine plus docetaxel for anthracycline-pretreated metastatic breast cancer (MBC) patients (pts) results of a European Phase III study. Proc. Am. Soc. Clin. Oncol.23(S24) (2005) (Abstract 581).
   Google Scholar
• Jones J, Takeda A, Tan SC et al. Gemcitabine for metastatic breast cancer. Health Technol. Assess.11(19), 1–81 (2006).
   Google Scholar
• Silberman G, Gupta S, Berkowitz N, Leyland-Jones B. Cost–effectiveness of capecitabine, continuous infusion 5-FU, gemcitabine and vinorelbine in the treatment of metastatic breast cancer. Proc. Am. Soc. Clin. Oncol. (1999) (Abstract 1629).
   Google Scholar
• Le Lay K, Payet S, Riou-Franca L, Chemali N, Launois R. A cost–utility analysis of first line chemotherapy regimens in the treatment of metastatic breast cancer after anthracyclines failure. ISPOR 8th Annual Congress. Palazzo Degli Affari, Florence, Italy (2005) (Abstract 5196).
   Google Scholar
• Eniu A, Carlson RW, Aziz Z et al. Global Summit Treatment and Allocation of Resources Panel. Breast cancer in limited-resource countries: treatment and allocation of resources. Breast J.12(Suppl. 1), S38–S53 (2006).
   PubMed Web of Science ®Google Scholar
• Loehrer PJ Sr, Elson P, Dreicer R et al. Escalated dosages of methotrexate, vinblastine, doxorubicin, and cisplatin plus recombinant human granulocyte colony-stimulating factor in advanced urothelial carcinoma: an Eastern Cooperative Oncology Group trial. J. Clin. Oncol.12(3), 483–488 (1994).
   PubMed Web of Science ®Google Scholar
• Saxman SB, Propert KJ, Einhorn LH et al. Long-term follow-up of a Phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J. Clin. Oncol.15(7), 2564–2569 (1997).
   PubMed Web of Science ®Google Scholar
• Logothetis CJ, Dexeus FH, Finn L et al. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J. Clin. Oncol.8(6), 1050–1055 (1990).
   PubMed Web of Science ®Google Scholar
• Lehmann J, Retz M, Stockle M. Is there standard chemotherapy for metastatic bladder cancer? Quality of life and medical resources utilization based on largest to date randomized trial. Crit. Rev. Oncol. Hematol.47(2), 171–179 (2003).
   Google Scholar
• Bepler G, Kusmartseva I, Sharma S et al. RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer. J. Clin. Oncol.24(29), 4731–4737 (2006).
   PubMed Web of Science ®Google Scholar
• Rosell R, Danenberg KD, Alberola V et al. Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin. Cancer Res.10(4), 1318–1325 (2004).
   PubMed Web of Science ®Google Scholar
• Ceppi P, Volante M, Novello S et al.ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. Ann. Oncol.17(12), 1818–1825 (2006).
   PubMed Web of Science ®Google Scholar
• Nakahira S, Nakamori S, Tsujie M et al. Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer. Int. J. Cancer120(6), 1355–1363 (2007).
   PubMed Web of Science ®Google Scholar
• Kwon WS, Rha SY, Choi YH et al. Ribonucleotide reductase M1 (RRM1) 2464G>A polymorphism shows an association with gemcitabine chemosensitivity in cancer cell lines. Pharmacogenet. Genomics16(6), 429–438 (2006).
   PubMed Web of Science ®Google Scholar
• Achiwa H, Oguri T, Sato S, Maeda H, Niimi T, Ueda R. Determinants of sensitivity and resistance to gemcitabine: the roles of human equilibrative nucleoside transporter 1 and deoxycytidine kinase in non-small cell lung cancer. Cancer Sci.95(9), 753–757 (2004).
   PubMed Web of Science ®Google Scholar
• Marce S, Molina-Arcas M, Villamor N et al. Expression of human equilibrative nucleoside transporter 1 (hENT1) and its correlation with gemcitabine uptake and cytotoxicity in mantle cell lymphoma. Haematologica91(7), 895–902 (2006).
   PubMed Web of Science ®Google Scholar
• Giovannetti E, Del Tacca M, Mey V et al. Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine. Cancer Res.66(7), 3928–3935 (2006).
   PubMed Web of Science ®Google Scholar